Mark Stolper
Known title: Executive VP and CFOCIK: 0001281961
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RadNet Q2 Earnings and AI Study News. RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.
Transaction History
| STLN | ▲ Buy | Grant | 31,124 | $0 | 7/27/2026 | View on chart |
| STLN | ▲ Buy | Grant | 25,833 | $0 | 7/7/2026 | View on chart |
| RDNT | ▲ Buy | Grant | 18,228 | $0 | 3/3/2026 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 35,703 | $217K | 12/10/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 35,000 | $2.6M | 9/16/2025 | View on chart |
| RDNT | ▲ Buy | Grant | 22,889 | $0 | 1/8/2025 | View on chart |
| RDNT | ▼ Sell | Gift | 275 | $0 | 12/16/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 25,000 | $1.5M | 6/10/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 14,072 | $0 | 3/1/2024 | View on chart |
| RDNT | ▼ Sell | Gift | 900 | $0 | 5/12/2023 | View on chart |
| RDNT | ▼ Sell | Gift | 375 | $0 | 5/4/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Starling Oncology reports stronger cash flow and gross profit
Starling Oncology disclosed higher cash flow and gross profit in its latest results. The improvement has prompted analysts to consider a re‑rating of the stock. The company’s financial metrics are now better positioned relative to its recent price range.
Starling Oncology reports stronger cash flow and gross profit. Starling Oncology disclosed higher cash flow and gross profit in its latest results. The improvement has prompted analysts to consider a re‑rating of the stock. The company’s financial metrics are now better positioned relative to its recent price range.